Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $10 from $9 and keeps a Buy rating on the shares after the company reported a beat and raise quarter. Paysign is “in the early innings of an inflection in pharma revenues,” according to the analyst, who believes “investors should take note.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAYS:
